- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Fabian Lang Discusses Provider-Patient Communication in CML
Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany, discussed the importance of good communication between health care providers and patients with chronic myeloid leukemia (CML).
Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany, discussed the importance of good communication between health care providers and patients with chronic myeloid leukemia.
Transcript
How can providers and health systems facilitate better communication between providers and patients?
I think, first of all, it's a kind of a balance of information. You need an informed patient who knows what therapies are available and how to deal with side effects and, as already mentioned, mainly focused on quality-of-life issues. And on the other hand, you need informed doctors who know about the medication, about the pitfalls, about the side effects, and how to bring both of them together. And apart from that, we have to learn about how to communicate with the patients in order to ensure compliance and efficacy, as I already elucidated.
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
